Amarpreet Sawhney is the CEO of Pramand, Rejoni, Pramand, Sealonix, and Rayz and Chairman of Instylla.  In the past he was Chairman, President and CEO of Ocular Therapeutix (NASDAQ: OCUL) focused on unmet needs in ophthalmic drug delivery and Chairman of Augmenix, Inc. focused in improving outcomes of radiotherapy.  Previously, he was Founder and CEO of Confluent Surgical (acquired by Covidien), a biosurgery company, the Chairman of MarketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence, technology founder of Focal, Inc. (acquired by Genzyme) and founder of Access Closure Inc. (acquired by Cardinal Health). He holds over 150 patents, which form the basis for several first-of-a-kind medical devices that have helped over 10 million patients worldwide. He is also General Partner of Incept LLC, a medical device accelerator which has created 26 companies in as many years.

Amar holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.